A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
JZP025-101 is an open-label, multicenter, multi-arm, nonrandomized phase 1b master trial to
determine the recommended phase 2 dose (RP2D) of CPX-351 when administered in combination
with various targeted agents in previously untreated subjects with Acute Myeloid Leukemia
(AML) who are fit to receive intensive chemotherapy (ICT). Subjects will be assigned to
treatment arms based on results of AML mutation testing.